Forte Biosciences IncNASDAQ FBRX Stock Report

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 6 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB-401, consists of three therapeutic strains of a commensal gram-negative bacteria, Roseomonas mucosa that is specifically selected for their impact on parameters of inflammatory skin disease. The company has completed a phase I/II a study, including both adults and pediatric patients, demonstrating reduction in atopic dermatitis disease and pruritus, as well as control of S. aureus while tapering/eliminating steroid use. Its subsidiaries include Forte Subsidiary, Inc., and Forte Biosciences Emerald Limited.